Value of MRI in evaluating urachal carcinoma: A single center retrospective study.

Autor: Das JP; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: dasj@mskcc.org., Woo S; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Ghafoor S; Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zürich, Switzerland., Andrieu PIC; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Ulaner GA; Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California., Donahue TF; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY., Goh AC; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY., Vargas HA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jazyk: angličtina
Zdroj: Urologic oncology [Urol Oncol] 2022 Jul; Vol. 40 (7), pp. 345.e9-345.e17. Date of Electronic Publication: 2022 Mar 26.
DOI: 10.1016/j.urolonc.2022.02.017
Abstrakt: Objectives: Urachal carcinomas (UrC) are rare non-urothelial bladder neoplasms, however the potential role for MR imaging in UrC has not been well established. Our objective was to assess the value of magnetic resonance imaging (MRI) in primary and recurrent UrC.
Methods and Materials: This retrospective single-center study included all patients with UrC that underwent MRI between January 2005 and May 2020. Two radiologists reviewed MRIs independently followed by consensus with a third radiologist. For primary UrC, tumor location, size, morphology, invasion of peritoneum and/or local structures other than bladder and concordance between Mayo stage on MRI and pathology were assessed. MRI performed for recurrent UrC evaluated the pattern of recurrence. The reference standard was histopathological analysis.
Results: Ninety-six patients with UrC were identified of which 17 were included (9 men and 8 women, median age 50 years [IQR 42-62]). At initial MR staging (n = 10), all primary UrC were located at the bladder dome with median longest axis dimension of 6.0 cm. Most (70%) were mixed solid-and-cystic. Invasion of the peritoneum and/or local structures other than bladder was identified in 30%. Concordance between consensus MRI Mayo stage and final pathologic Mayo stage was 90%. At MR restaging (n = 7), UrC recurrence was most commonly seen at the bladder dome (71%). Overall, MRI showed a sensitivity of 85% and specificity of 50% for detecting recurrent tumor.
Conclusion: MRI demonstrates value in evaluation of disease extent in primary and recurrent UrC, with high concordance between Mayo stage at MRI and pathology, and in the detection of local recurrences.
Competing Interests: Conflict of interest This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. Alvin C. Goh is a consultant to Medtronics for provision of Services for which he does not receive compensation. The other authors do not have anything to disclose.
(Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: